CLYM Climb Bio, Inc.

NASDAQ
$9.30

Climb Bio, Inc. (CLYM) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.9% since its last earnings release on November 5, 2026.

Climb Bio Beat Consensus Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.19)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Climb Bio, Inc.

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.